<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02968927</url>
  </required_header>
  <id_info>
    <org_study_id>TBHDT-AUR1-8-178</org_study_id>
    <nct_id>NCT02968927</nct_id>
  </id_info>
  <brief_title>TB Host Directed Therapy</brief_title>
  <acronym>TBHDT</acronym>
  <official_title>A Ph2 Randomized Trial to Evaluate the Safety Preliminary Efficacy and Biomarker Response of Host Directed Therapies Added to Rifabutin-modified Standard Therapy in Adults With Drug-Sensitive Smear-Positive Pulmonary TB</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Aurum Institute NPC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Aurum Institute NPC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To examine the safety and preliminary efficacy of multiple adjunctive host directed TB&#xD;
      therapies (TB HDT), to assess their potential to shorten TB treatment and/or prevent&#xD;
      permanent lung damage.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      To determine the safety and preliminary efficacy of 4 TB HDT candidates:&#xD;
&#xD;
        1. Safety (treatment emergent serious adverse events and SUSARs)&#xD;
&#xD;
        2. Microbiologic effects in sputum (culture conversion, change in MGIT TTP) and blood (WBA)&#xD;
&#xD;
        3. PET/CT imaging&#xD;
&#xD;
        4. Serum markers of inflammation&#xD;
&#xD;
        5. Effects on Mtb-specific and general immune function&#xD;
&#xD;
        6. Pulmonary effects (spirometry, 6MWT, O2 saturation, and St. George Respiratory Symptom&#xD;
           Questionnaire) In each case, TB HDT effects will be determined by comparison to patients&#xD;
           treated with standard TB therapy alone with regard to a common set of primary and&#xD;
           secondary endpoints.&#xD;
&#xD;
      PRIMARY ENDPOINTS&#xD;
&#xD;
        1. For auranofin, everolimus, and vitamin D: the proportions of patients experiencing&#xD;
           suspected unexpected serious adverse reactions (SUSARs).&#xD;
&#xD;
        2. For CC-11050: the proportion of patients experiencing treatment emergent serious adverse&#xD;
           events (SAEs).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">November 2016</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Actual">September 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SAEs and SUSARs</measure>
    <time_frame>through day 180</time_frame>
    <description>For auranofin, everolimus, and vitamin D: the proportions of patients experiencing suspected unexpected serious adverse reactions (SUSARs).&#xD;
For CC-11050: the proportion of patients experiencing treatment emergent serious adverse events (SAEs).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>TEAEs other than SAEs and SUSARs</measure>
    <time_frame>through day 180</time_frame>
    <description>TEAEs other than SAEs, categorized according to severity, drug relatedness, and leading to early withdrawal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sputum culture status on day 56</measure>
    <time_frame>day 56</time_frame>
    <description>Proportion of patients with positive sputum cultures on solid culture medium after 8 weeks of treatment</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in FEV1 from baseline to 2 and 6 months</measure>
    <time_frame>days 56 and 180</time_frame>
    <description>FEV1 (% of expected value)</description>
  </other_outcome>
  <other_outcome>
    <measure>18F-FDG PET/CT imaging (change from baseline to 2 months):</measure>
    <time_frame>day 56</time_frame>
    <description>Maximum and mean standardized uptake values (SUV)</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum neopterin</measure>
    <time_frame>day 56</time_frame>
    <description>change from baseline b. CRP</description>
  </other_outcome>
  <other_outcome>
    <measure>Quantiferon gold in tube</measure>
    <time_frame>day 56</time_frame>
    <description>change from baseline</description>
  </other_outcome>
  <other_outcome>
    <measure>Gene expression profiles (exploratory)</measure>
    <time_frame>days 56 and 180</time_frame>
    <description>Change from baseline to 2 and 6 months in gene expression profiles</description>
  </other_outcome>
  <other_outcome>
    <measure>PD-1 expression (exploratory)</measure>
    <time_frame>days 56 and 180</time_frame>
    <description>PD-1 expression on CD4 and CD8 lymphocytes</description>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>2HRbEZ/4HRb</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2HRbZE</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Everolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Everolimus 0.5 MG</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Auranofin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Auranofin 6 MG</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vitamin D3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CC-11050</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CC-11050</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus 0.5 MG</intervention_name>
    <arm_group_label>Everolimus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Auranofin 6 MG</intervention_name>
    <arm_group_label>Auranofin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <arm_group_label>Vitamin D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CC-11050</intervention_name>
    <arm_group_label>CC-11050</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2HRbZE/4HRb</intervention_name>
    <arm_group_label>2HRbEZ/4HRb</arm_group_label>
    <arm_group_label>Auranofin</arm_group_label>
    <arm_group_label>CC-11050</arm_group_label>
    <arm_group_label>Everolimus</arm_group_label>
    <arm_group_label>Vitamin D</arm_group_label>
    <other_name>rifabutin-modified TB therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Willing and able to provide signed written consent or witnessed oral consent in the&#xD;
             case of illiteracy, prior to undertaking any trial-related procedures.&#xD;
&#xD;
          2. Aged 18 to 65 years, male, or if female, either not of reproductive potential&#xD;
             (post-menopause, or status-post surgical sterilization) or with an intrauterine&#xD;
             contraceptive device in place.&#xD;
&#xD;
          3. Body weight (in light clothing without shoes) between 40 and 90 kg.&#xD;
&#xD;
          4. First episode of pulmonary tuberculosis diagnosed by positive sputum AFB smear with&#xD;
             subsequent culture confirmation OR positive Xpert TB/RIF with Ct &lt;20 [4].&#xD;
&#xD;
          5. RIF susceptibility diagnosed by Xpert TB/RIF OR Hain test&#xD;
&#xD;
          6. Chest radiograph meeting criteria for moderate or far advanced pulmonary tuberculosis&#xD;
             [5]&#xD;
&#xD;
          7. HIV-1 seronegative&#xD;
&#xD;
          8. HBsAg negative&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any condition for which participation in the trial, as judged by the investigator,&#xD;
             could compromise the well-being of the subject or prevent, limit or confound protocol&#xD;
             specified assessments&#xD;
&#xD;
          2. Current or imminent treatment for malaria.&#xD;
&#xD;
          3. Is critically ill, and in the judgment of the investigator has a diagnosis likely to&#xD;
             result in death during the trial or the follow-up period.&#xD;
&#xD;
          4. TB meningitis or other forms of severe tuberculosis with high risk of a poor outcome&#xD;
             as judged by the investigator.&#xD;
&#xD;
          5. History of allergy or hypersensitivity to any of the trial therapies or related&#xD;
             substances, including known allergy or suspected hypersensitivity to rifampin or&#xD;
             rifabutin.&#xD;
&#xD;
          6. Having participated in other clinical trials with investigational agents within 8&#xD;
             weeks prior to trial start or currently enrolled in an investigational trial.&#xD;
&#xD;
          7. Subjects with any of the following at screening:&#xD;
&#xD;
               1. Cardiac arrhythmia requiring medication;&#xD;
&#xD;
               2. Prolongation of QT/QTc interval with QTcF (Fridericia correction) &gt;450 ms;&#xD;
&#xD;
               3. History of additional risk factors for Torsade de Pointes, (e.g., heart failure,&#xD;
                  hypokalemia, family history of Long QT Syndrome);&#xD;
&#xD;
               4. Any clinically significant ECG abnormality, in the opinion of the investigator.&#xD;
&#xD;
               5. Patients requiring concomitant medications that prolong the QT inter-val.&#xD;
&#xD;
          8. Random blood glucose &gt;140 mg/dL, or history of unstable Diabetes Mellitus which&#xD;
             required hospitalization for hyper- or hypoglycaemia within the past year prior to&#xD;
             start of screening.&#xD;
&#xD;
          9. Use of systemic corticosteroids within the past 28 days.&#xD;
&#xD;
         10. Subjects with any of the following abnormal laboratory values:&#xD;
&#xD;
               1. creatinine &gt;2 mg/dL&#xD;
&#xD;
               2. haemoglobin &lt;8 g/dL&#xD;
&#xD;
               3. platelets &lt;100x109 cells/L&#xD;
&#xD;
               4. serum potassium &lt;3.5&#xD;
&#xD;
               5. aspartate aminotransferase (AST) ≥2.0 x ULN&#xD;
&#xD;
               6. alkaline phosphatase (AP) &gt;5.0 x ULN&#xD;
&#xD;
               7. total bilirubin &gt;1.5 mg/dL&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert S Wallis, MD,FIDSA</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Aurum Institute NPC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Aurum Institute: Tembisa Clinical Research Centre</name>
      <address>
        <city>Tembisa</city>
        <state>Gauteng</state>
        <zip>1736</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>September 8, 2016</study_first_submitted>
  <study_first_submitted_qc>November 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2016</study_first_posted>
  <last_update_submitted>January 9, 2019</last_update_submitted>
  <last_update_submitted_qc>January 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Rifabutin</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Auranofin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

